Sangamo Q4 revenue misses analyst expectations

Overview

• Genomic medicine firm's Q4 revenue rose yr/yr but missed analyst expectations

• Company posted Q4 net loss of $37.4 mln, or $0.11 per share

• Raised over $130 mln since start of 2025 through licensing, milestones and equity financing

Outlook

• Sangamo expects 2026 GAAP operating expenses of $120 mln to $140 mln, subject to funding

• Company sees 2026 non-GAAP operating expenses at $110 mln to $120 mln, excluding stock comp and D&A

• Sangamo expects current cash and recent financings to fund operations into Q3 2026

Result Drivers

• PFIZER LICENSE PAYMENT - Q4 revenue increase was mainly due to $6 mln in revenue from Pfizer’s exercise of a licensing option

• INCREASED CLINICAL AND MANUFACTURING COSTS - Higher Q4 operating expenses were driven by increased clinical and manufacturing costs related to BLA readiness for the Fabry disease program

• IMPAIRMENT CHARGES - Q4 operating expenses rose due to impairment charges on long-lived assets

Company press release: ID:nGNX5D3V0C

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 523.2% above its March 27 closing price of $0.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.